Pharmacokinetics of omeprazole in cirrhotic patients

M. Rinetti, M. B. Regazzi, P. Villani, M. Tizzoni, R. Sivelli

Research output: Contribution to journalArticlepeer-review


Omeprazole (CAS 73590-58-6), an H+, K+ ATPase inhibitor, is a potent suppressor of gastric acid secretion and a very active substance in the treatment of duodenal and gastric ulcers. The kinetic profile of omeprazole is well defined for healthy volunteers and for some high-risk populations, but not so far for patients with liver disease. As the substance is mainly metabolized in the liver, changes in liver circulation and/or function might lead to changes in the pharmacokinetics of omeprazole. Aim of the study was to evaluate the kinetic profile in patients with liver disease and compare the results obtained in healthy volunteers. 16 subjects were included in the study: 8 patients with liver cirrhosis and 8 healthy volunteers. A single oral dose of omeprazole 20 mg was administered: plasma samples were collected for 24 h since omeprazole administration. The principal pharmacokinetic parameters were estimated for the two studied populations.

Original languageEnglish
Pages (from-to)420-422
Number of pages3
JournalArzneimittel-Forschung/Drug Research
Issue number4
Publication statusPublished - 1991


  • Antiulcer drugs
  • CAS 73590-58-6
  • Cirrhosis, hepatic
  • Omeprazole, clinical pharmacokinetics

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Pharmacokinetics of omeprazole in cirrhotic patients'. Together they form a unique fingerprint.

Cite this